StockNews.com upgraded shares of Codexis (NASDAQ:CDXS – Get Rating) from a sell rating to a hold rating in a research note published on Saturday.

Separately, HC Wainwright cut their target price on shares of Codexis from $25.00 to $15.00 and set a buy rating for the company in a research report on Monday, November 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Codexis currently has an average rating of Moderate Buy and a consensus price target of $19.67.

Codexis Price Performance

NASDAQ CDXS opened at $4.43 on Friday. Codexis has a fifty-two week low of $4.40 and a fifty-two week high of $34.63. The stock's 50-day moving average is $5.52 and its two-hundred day moving average is $7.16. The firm has a market cap of $290.99 million, a P/E ratio of -9.23 and a beta of 1.45.

Insider Buying and Selling at Codexis

In related news, Director John J. Nicols sold 35,714 shares of the business's stock in a transaction on Monday, December 12th. The stock was sold at an average price of $5.68, for a total value of $202,855.52. Following the sale, the director now owns 863,535 shares of the company's stock, valued at approximately $4,904,878.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director John J. Nicols sold 35,714 shares of the business's stock in a transaction that occurred on Monday, December 12th. The shares were sold at an average price of $5.68, for a total value of $202,855.52. Following the completion of the transaction, the director now owns 863,535 shares in the company, valued at approximately $4,904,878.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John J. Nicols sold 35,716 shares of the firm's stock in a transaction on Friday, October 28th. The stock was sold at an average price of $5.53, for a total value of $197,509.48. Following the completion of the transaction, the director now owns 943,106 shares in the company, valued at $5,215,376.18. The disclosure for this sale can be found here. Insiders sold a total of 146,931 shares of company stock valued at $839,487 in the last quarter. Corporate insiders own 7.00% of the company's stock.

Institutional Trading of Codexis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Swiss National Bank boosted its stake in Codexis by 8.1% in the 1st quarter. Swiss National Bank now owns 138,000 shares of the biotechnology company's stock valued at $2,846,000 after purchasing an additional 10,300 shares during the period. JPMorgan Chase & Co. increased its holdings in Codexis by 20.5% in the 1st quarter. JPMorgan Chase & Co. now owns 52,116 shares of the biotechnology company's stock worth $1,075,000 after purchasing an additional 8,870 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Codexis by 0.7% in the 1st quarter. Bank of New York Mellon Corp now owns 220,879 shares of the biotechnology company's stock valued at $4,554,000 after buying an additional 1,618 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Codexis by 33.8% during the first quarter. American Century Companies Inc. now owns 820,630 shares of the biotechnology company's stock worth $16,921,000 after purchasing an additional 207,107 shares during the period. Finally, US Bancorp DE lifted its holdings in Codexis by 517.5% during the 1st quarter. US Bancorp DE now owns 8,380 shares of the biotechnology company's stock worth $172,000 after buying an additional 7,023 shares during the period. 93.41% of the stock is owned by institutional investors.

Codexis Company Profile

(Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Featured Stories

• Get a free copy of the StockNews.com research report on Codexis (CDXS)
• Three Healthcare Penny Stocks to Watch In The New Year
• Southwest Airlines Stock, There is a Lot to Love
• MarketBeat: Week in Review 12/19 – 12/23
• These Steelmakers Deserve A Place On Your 2023 Watch List
• Inflation Cools, Where Does The S&P 500 Go Now

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.